The Study of Interfering of Endogenous VEGF-C Genes and the Protein Expression Gastric Cancer Cell with siRNA Technique

GUO Mei-mei, WANG Yong, HAN Fang-hai

Abstract

To explore the interfering effects of siRNA on endogenous VEGF-C genes and the protein expression in gastric cancer cells. Methods Cultured gastric cancer cell line SGC7901 cells were prepared in vitro. Five siRNA primers of VEGF-C were designed depending on the sequence of Accession No.BC035212.1 in Genbank. After homology analysis, the primers were synthesized and transfected into SGC7901 cells. The endogenous VEGF-C mRNA level and its protein expression were observed. Results VEGF-C-siRNA was inserted into the gastric cancer cell successfully. Five siRNA primers of VEGF-C could inhibit VEGF-C genes and protein expression. Conclusion siRNA could block the endogenous VEGF-C genes and the protein expression in gastric cancer cell.

 

Keywords: Gastric cancer, Lymph vessel growth factor, siRNA, In vitro

 

Full Text:

PDF


References


Dixelius J. Makinen T, Wirzenius M, et al. Ligand-induced vascular endothelial growth factor receptor-3 ( VEGFR-3 ) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem,2003;278(42);40973-40979.

Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor VEGF-C is a ligand for the flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinasese. EMBO J ,1996; 15(5):290-295.

Breslin JW. Yuan SY, Wu MH. VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism. Lymphat Res Biol, 2007; 5 (2):105-113.

Karpanen М, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor С promotes tumour lymphangiogenesis and intralymphatic tumour growth. Cancer Res.2001;61(11):1786-1790.

Witzenhichler B, Asahara T, Murohara T, et al. Vascular endothelial growth factor-C ( VEGF-С/VEGF-2 ) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol, 1998;153(2):381-394.

Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol,2003; 162(2);575-586.

Duff SE, Li C, Renehan AO, et al. Immunodetection and molecular forms of plasma vascular endothelial growth factor- с. Int J Oncol,2003;22(2):339-343.

Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res,2002;62(5): 1315-1320.

Ishikawa M, Kitayama J, Kazama S, et al. Expression of vascular endothelial growth factor (VEGF)-C in preoperative biopsy specimens and metastatic foci of regional lymph nodes in submucosal gastric carcinoma. World J Surg Oncol, 2005; 3 (0:1172-1179.

Tanaka K, Nishioka J, Kato K, et al. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res, 2001; 92 ( 9 ); 952- 958.

Bikfalvil A, Moenner M, Javerzat S, et al. Inhibition of angiogenesis and the angiogenesis/invasion shift. Biochem Soc Trans,2011;39(6) ;89-93.

Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989; 161(2) :851-858.

Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med,2010;207(3):491-503.

Wagner AD, Arnold D, Grothey AA, et al. Anti-angiogenic therapies for metastatic colorectal cancer. J Cancer Res, 2009; 87(9);95-99.

Saranadasa M. Wang ES. Vascular endothelial growth factor inhibition; conflicting roles in tumor growth. Cytokine, 2011; 53(2):115-129.

Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA, 2011; 108 (5):3749-3754.

Torben FH, Anders J. Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. Pharmacogenomics,2011; 12( 12): 1681-1693.

Baluk P, Hashizume H. McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev, 2005;15(3);102-111.


Refbacks

  • There are currently no refbacks.